The DOI matches its Crossref record.
A resurrection of aducanumab for Alzheimer's disease
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“since it is known that the Aβ plaques act as a driver of AD pathology63 and the accumulation Aβ plaques in the brain initiates a complex multicellular neurodegenerative process.”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [66]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sorted by citations
Items 201–224 of 224
Psychological impact of biomarker-assisted diagnosis of Alzheimer's disease
Landry, A., Elsliger, S., Gaudet, J., Al‐Shamaa, S., & Chamard-Witkowski, L. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251341587 · Cited by 1
“11,12 Furthermore, these treatments are not accessible in many countries and can only be given to a limited number of patients who meet speci fi c criteria.”
Wasielewska, J. M., Cabral-da-Silva, M. C., Pecoraro, M., Nguyen, T. H., Bella, V. L., Oikari, L. E., Ooi, L., & White, A. R. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.22.581567 · Cited by 1
Basic Concepts, Hypotheses and Drug Development of Alzheimer's Disease
Zhang, J. (2023) · Theoretical and Natural Science · doi:10.54254/2753-8818/3/20220484 · Cited by 1
Bell, S., Wareing, H., Hamshaw, A., De, S., New, E. J., Shaw, P., Marco, M. D., Venneri, A., Blackburn, D. J., Ferraiuolo, L., et al. (2023) · bioRxiv · doi:10.1002/alz.074618 · Cited by 1
Gvazava, N., Konings, S., Cepeda-Prado, E., Skoryk, V., Umeano, C. H., Dong, J., Silva, I. A. N., Ottosson, D., Leigh, N. D., Wagner, D., et al. (2023) · bioRxiv · doi:10.1101/2023.01.05.522847 · Cited by 1
Harrison, C. H., Sakai, K., Johnston, D. A., Holmes, C., Boche, D., & Nicoll, J. A. R. (2022) · medRxiv · doi:10.1101/2022.12.08.22283144
Historical efforts to develop 99mTc-based amyloid plaque targeting radiotracers
Takalloobanafshi, G., Kukreja, A., & Hicks, J. (2022) · Frontiers in Nuclear Medicine · doi:10.3389/fnume.2022.963698 · Cited by 1
“All three bore a 2-phenylbenzothiazole core with different bifunctional chelators used: a mercaptoacetyltriglycine (MAG3; 8), a hydrazinonicotinic acid (HYNIC)/tricine (9), and an imino-diacetic acid (10).”
BackgroundHoy, K., Emonson, M. R. L., Bailey, N., Rogers, C., Coyle, H. L., Stockman, F., & Fitzgerald, P. (2022) · medRxiv · doi:10.1101/2022.02.21.22271264 · Cited by 1
Research Progress in Alzheimer’s Disease
张, 苹. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1472138 · Cited by 3
Sigma-1 Receptor Ligand Blarcamesine (ANAVEX 2-73) for Alzheimer’s Disease: A Systematic Review
Brimson, S., Thitilertdecha, P., Kumaree, K., & Brimson, J. (2026) · CNS Drugs · doi:10.1007/s40263-026-01327-3
Cools, L., Dahdouh-Guebas, Y., Kemps, I., Bergmans, S., Castelein, J., Vandenbroucke, R. E., Hoecke, L. V., & Groef, L. D. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02249-3
“Regulatory responses have reflected these limitations: the EMA declined approval for Aducanumab and Don-anemab, while Lecanemab received conditional approval in 2025 for a genetically defined subgroup of patients [4, 5].”
Boussoufa, K., Lesclide, E., Bonin-Guillaume, S., Campana, M., Grino, M., & Franqui, C. (2024) · Geriatric Nursing · doi:10.1016/j.gerinurse.2024.08.027
Yashkin, A. P., Kolpakov, S. A., Ukraintseva, S. V., Yashin, A. I., & Akushevich, I. V. (2024) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-024-00170-z · Cited by 1
Yashkin, A., Nikitin, S. K., Gorbunova, G., Kravchenko, J., Yashin, A., & Akushevich, I. (2023) · Research Square · doi:10.21203/rs.3.rs-2596630/v1
Dementia Diagnosis and Alternate Treatment: A Recent Update on Treatment Options
Gupta, U. D., Shafin, T. N., Rahman, N., Chakraborty, E., Deb, M., & Ferdous, T. (2023) · Asian Journal of Medicine and Health · doi:10.9734/ajmah/2023/v21i10874
“Moreover, full results of these papers have not been published in peerreviewed form [19-21].”
BackgroundMüller, S., van Oosterhout, A., Bervoets, C., Christen, M., Martínez-Álvarez, R., & Bittlinger, M. (2022) · Neuroethics · doi:10.1007/s12152-022-09485-z · Cited by 20
“Whether the antibody aducanumab is effective for Alzheimer’s dementia in higher doses has yet to be determined [137].”
BackgroundPotential Roles of α-amylase in Alzheimer’s Disease: Biomarker and Drug Target
Chen, W. N., Tang, K. S., & Yeong, K. Y. (2021) · Current Neuropharmacology · doi:10.2174/1570159x20666211223124715 · Cited by 7
“Aducanumab, a monoclonal antibody, selectively binds to human B-cell clones triggered by neo-epitopes present in pathological Aβ aggregates, reducing brain Aβ plaques [78, 79].”
Ramírez, U. A. T., Medina, M. E., Ruiz, A. P. R., Borja, M. D. L. Á. S., & Ricoy, O. U. D. (2021) · Lux Médica · doi:10.33064/48lm20212964 · Cited by 1
El anticuerpo aducanumab en la enfermedad de Alzheimer
Bombón-Albán, P. E. (2021) · Neurología Argentina · doi:10.1016/j.neuarg.2021.07.002
Specific Aspects and Significance of Subgroup Assessment in Confirmatory Clinical Trials
Basova, O. I., Lysikova, I. V., & Ivanova, O. Y. (2021) · The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products Regulatory Research and Medicine Evaluation · doi:10.30895/1991-2919-2021-11-2-81-93
“исследования и не имеющих значительных отклонений от протокола [10].”
The Current Advance of Clinical Drug for Treatment Alzheimer’s Disease and the Research of New Drug
Yazhen, S. (2020) · Archives in Neurology & Neuroscience · doi:10.33552/ann.2020.09.000701
“Akatinol Memantine N-methyl-D-aspartate (NMDA) receptor antagonist, the first drug approved by FDA for the treatment of moderate to severe AD.”
MethodInfluentialGene and cell therapy for the nucleus basalis of Meynert with NGF in Alzheimer's disease
Eriksdotter, M., & Mitra, S. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819975-6.00012-1 · Cited by 3
Huang, Y. H., Jia, H., & Bao, W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816475-4.00013-6
Pulling It All Together: A Drug Development Case History
Zanders, E. (2020) · The Science and Business of Drug Discovery · doi:10.1007/978-1-4419-9902-3_15
Metadata
- Authors
- Schneider, L.
- Corresponding author
- Schneider, Lon
- ORCID
- Schneider, Lon
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 19
- Issue
- 2
- Pages
- 111-112
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W2992893037
- Cited by
- 286
- References
- 0
- Citations by year
- 2026: 5 · 2025: 18 · 2024: 27 · 2023: 45 · 2022: 55 · 2021: 76 · 2020: 59
- FWCI
- 32.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- aducanumab, Alzheimer's disease, anti-amyloid antibodies, Biogen, data reanalysis, anti-amyloid therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
